These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28571245)

  • 1. Rituximab: A Magic Bullet for Pemphigus.
    Anandan V; Jameela WA; Sowmiya R; Kumar MMS; Lavanya P
    J Clin Diagn Res; 2017 Apr; 11(4):WC01-WC06. PubMed ID: 28571245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
    De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
    Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose rituximab as an adjuvant therapy in pemphigus.
    Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
    Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases.
    Mahajan VK; Sharma NL; Sharma RC; Garg G
    Int J Dermatol; 2005 Oct; 44(10):821-7. PubMed ID: 16207182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
    Joly P; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Vermeulin T; Benichou J; Musette P;
    Lancet; 2017 May; 389(10083):2031-2040. PubMed ID: 28342637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
    Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
    Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real world evidence: Patients with refractory pemphigus treated with Rituximab.
    Perifani V; Dalamaga M; Theodoropoulos K; Theotokoglou S; Syrmali A; Loumou P; Papadavid E
    Metabol Open; 2021 Dec; 12():100142. PubMed ID: 34746731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Demographic Attributes, Clinical Features, and Optimal Management of 143 Patients with Pemphigus: A Retrospective Observational Study from a Tertiary Care Center of India.
    Mahajan VK; Mehta KS; Sharma J; Kumar P; Chauhan PS; Singh R; Manvi S; Vashist S; Sharma A; Sharma AL
    Indian Dermatol Online J; 2022; 13(2):207-215. PubMed ID: 35287415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
    Ahmed AR; Shetty S
    Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in Pemphigus - An Observational Study from a Tertiary Care Center of North India.
    Hassan I; Rehman F; Sultan SJ; Aslam A; Tasaduq I; Reyaz S
    Indian Dermatol Online J; 2022; 13(5):620-624. PubMed ID: 36304644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
    Miše J; Jukić IL; Marinović B
    Front Immunol; 2022; 13():884931. PubMed ID: 35592312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparative Study to Evaluate the Efficacy and Cost of Rituximab versus Dexamethasone Cyclophosphamide Pulse in Patients of Pemphigus Vulgaris.
    Das S; Agarwal K; Singh S; Halder D; Sinha S; De A
    Indian J Dermatol; 2021; 66(2):223. PubMed ID: 34188295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience of Rituximab Therapy in Pemphigus: A Three-Year Retrospective Study from a Sub-Himalayan State.
    Verma G; Sharma A; Rattan R; Negi A; Gupta M; Sharma R
    Indian J Dermatol; 2022; 67(4):477. PubMed ID: 36578732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety analysis of single cycle of biosimilar rituximab in pemphigus: A retrospective study of 76 patients from India.
    Shah BJ; Mistry D; Shah SR
    Dermatol Ther; 2022 Sep; 35(9):e15704. PubMed ID: 35808907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
    Grando SA
    Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
    Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
    Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable remission of pemphigus with a fixed-dose rituximab protocol.
    Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
    JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.